China NT Pharma Group (HKG:1011) expects an attributable loss of between 35 million yuan and 37 million yuan for the ten months ended Oct. 31, 2024, down from 152.9 million yuan a year prior, a Wednesday bourse filing said.

The drugmaker attributed the upbeat forecast to the absence of loss from the proprietary pharmaceutical product business and a one-off consultancy fee incurred in the year-ago period.